Search Results for "Pregnancy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pregnancy. Results 251 to 260 of 981 total matches.
Perampanel (Fycompa) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Feb 03, 2014 (Issue 1435)
; it is
classified as a schedule III controlled substance.
Pregnancy – Perampanel is classified as category C ...
Perampanel (per am’ pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has
been approved by the FDA for adjunctive treatment of
partial-onset seizures in patients ≥12 years old. New
drugs for epilepsy are often initially approved by the
FDA as adjunctive treatment for partial seizures.
Certolizumab Pegol (Cimzia) and Ustekinumab (Stelara) for Psoriatic Arthritis
The Medical Letter on Drugs and Therapeutics • Feb 03, 2014 (Issue 1435)
for tuberculosis is recommended
before treatment.
Pregnancy – All of the TNF inhibitors and ustekinumab ...
Certolizumab pegol (Cimzia – UCB), a tumor necrosis
factor (TNF) inhibitor previously approved for treatment
of Crohn's disease and rheumatoid arthritis,
and ustekinumab (Stelara – Janssen), a human interleukin-12 and -23 antagonist previously approved for
treatment of moderate-to-severe plaque psoriasis,
have now been approved by the FDA for treatment of
active psoriatic arthritis.
Extended-Release Oxycodone and Acetaminophen (Xartemis XR)
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014 (Issue 1447)
studies) for use during pregnancy.
Prolonged use of opioids during pregnancy can result
in neonatal ...
The FDA has approved a fixed-dose extended-release
formulation of oxycodone and acetaminophen
(Xartemis XR – Mallinckrodt) for oral treatment of
acute pain severe enough to require an opioid. Oxycodone
is available in the US as a single entity in oral
immediate-release (Oxecta, and others) and extendedrelease
(OxyContin) formulations. Immediate-release
oxycodone is also available in combination with aspirin
(Percodan, and others), acetaminophen (Percocet,
and others), or ibuprofen (see Table 1).
Ferric Citrate (Auryxia) for Hyperphosphatemia
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015 (Issue 1483)
.
PREGNANCY — Ferric citrate is classified as category
B (no adequate studies in animals or women;
risk ...
The FDA has approved ferric citrate (Auryxia –
Keryx), an oral phosphate binder, for treatment of
hyperphosphatemia in patients with chronic kidney
disease (CKD) on dialysis. It is the second iron-based
phosphate binder to be approved in the US, and the
first that causes significant systemic absorption of
iron. Auryxia is not FDA-approved for treatment of
iron deficiency anemia.
A New Abuse-Deterrent Opioid - Xtampza ER
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
with Xtampza ER.
PREGNANCY — As with other opioid analgesics,
prolonged use of Xtampza ER during pregnancy ...
The FDA has approved Xtampza ER (Collegium),
a new extended-release, abuse-deterrent capsule
formulation of oxycodone, for management of pain
severe enough to require daily, around-the-clock,
long-term opioid treatment and for which alternative
treatment options are inadequate.
L-Glutamine (Endari) for Sickle Cell Disease
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018 (Issue 1539)
(12% vs 8%).
PREGNANCY AND LACTATION — No data are available
on the use of Endari during pregnancy ...
The FDA has approved an oral powder formulation
of the amino acid L-glutamine (Endari – Emmaus) to
reduce the acute complications of sickle cell disease
in patients ≥5 years old. Endari is only the second
drug to be approved for use in sickle cell disease; the
antimetabolite hydroxyurea (Droxia) was approved
20 years ago. L-glutamine oral powder is also
available by prescription as NutreStore for treatment
of short bowel syndrome and over the counter as a
dietary supplement.
Brexanolone (Zulresso) for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
allopregnanolone, the major metabolite of
progesterone. Allopregnanolone levels rise during
pregnancy, peak ...
The FDA has approved the GABAA receptor modulator
brexanolone (Zulresso – Sage Therapeutics) for
IV treatment of postpartum depression (PPD).
Brexanolone is the first drug to be approved by the FDA
for this indication.
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
reaction to any
component of the vaccine.3
PREGNANCY AND LACTATION — Pregnant women
with COVID-19 ...
The FDA has issued an Emergency Use Authorization
(EUA) for the Pfizer-BioNTech mRNA-based vaccine
for prevention of COVID-19 in persons ≥16 years old.
FDA Authorizes Moderna COVID-19 Vaccine
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
after
vaccination.4
PREGNANCY AND LACTATION — Pregnant women
with COVID-19 are at increased risk ...
On December 18, 2020, the FDA issued an Emergency
Use Authorization (EUA) for the Moderna mRNA-based
vaccine for prevention of COVID-19 in persons
≥18 years old. The Pfizer-BioNTech mRNA-based
vaccine received an FDA EUA for the same indication
in persons ≥16 years old on December 11, 2020.
Maribavir (Livtencity) for Cytomegalovirus Infection (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
.
PREGNANCY AND LACTATION — No data are available
on the use of maribavir during pregnancy. In a study ...
Maribavir (Livtencity – Takeda), an oral cytomegalovirus
(CMV) pUL97 kinase inhibitor, has been
approved by the FDA for treatment of post-transplant
CMV infection refractory to standard antiviral therapy
in patients ≥12 years old who weigh at least 35 kg.